Oric Pharmaceuticals
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average and near the bottom of the universe on momentum.
- Signal has read STRONG SELL for 4 weeks.
- Its last 9 Sell calls were actually followed by a +14% average gain three months out - this one has bounced back faster than the signal expected.
- Recent price momentum is -41.4% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has fallen to 10.4% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-22 08:27 UTC
Data coverage: 4 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation N/A
How expensive the stock is versus earnings, sales and its own 5-year history.
Not enough data to grade this factor.
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability D-
How much profit the business keeps from each dollar of sales and capital.
| Return on equity | -41.3% | Better than 10% |
| Return on invested capital | -40.8% | Better than 7% |
Momentum C-
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -48.2% | Better than 6% |
| 6-month return | -11.5% | Better than 38% |
| 12-month return (ex latest month) | 13.3% | Better than 51% |
| Distance below 52-week high | 49.9% | Better than 18% |
Financial Health A+
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 14.1x | Better than 96% |
| Debt to assets | 0.8% | Better than 94% |
Analyst View A+
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 100.0% | Better than 77% |
| Upside to average target | 220.2% | Better than 95% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 7.70
- Open
- 7.58
- Day range
- 7.28 - 8.00
- Avg price
- 7.42
- Volume
- 1.46M
- Turnover
- 10.81M
- Turnover ratei
- 1.52%
- Volume ratioi
- 1.09
- Amplitudei
- 9.42%
- 52-week rangei
- 7.23 - 14.68
Valuation
- P/Ei
- -5.01
- P/E (TTM)i
- -5.11
- P/Bi
- 2.25
- EPSi
- -1.47
- Book value / shi
- 3.27
- Net profit
- -152.78M
- Net assets
- 339.54M
Share structure
- Market cap
- 764.94M
- Float capi
- 704.32M
- Shares out
- 103.93M
- Float sharesi
- 95.70M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2020-04-24
49.9% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-1.55M net over the window
Short interest
- Shares short
- 10.73M
- % of floati
- 10.35%
- Days to coveri
- 4.80
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Oric Pharmaceuticals (ORIC)?
Oric Pharmaceuticals last traded at 7.36. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Oric Pharmaceuticals's market cap?
About 764.94M.
What is the P/E ratio of Oric Pharmaceuticals?
The trailing twelve-month P/E is -5.11. The Valuation tab shows it against the stock's own five-year range.
Does Oric Pharmaceuticals pay a dividend?
Oric Pharmaceuticals does not currently pay a regular dividend.
Is Oric Pharmaceuticals a buy according to analysts?
The consensus of 8 analysts is a Buy rating, with an average 12-month price target of 23.57, which implies 220.2% upside from the current price. This is not investment advice.
What is Oric Pharmaceuticals's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Oric Pharmaceuticals a E (Strong Sell). Below its 200-day average and near the bottom of the universe on momentum. Not investment advice.
Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.
Oric Pharmaceuticals discussion 0 comments